October 10, 2007 - Medtronic Inc. announced that an FDA advisory committee has recommended the Endeavor drug-eluting stent for conditional approval as a treatment for coronary artery disease, positioning the Endeavor stent to become the first new drug-eluting stent to be introduced in the United States since 2004.

October 10, 2007 - Premier Purchasing Partners, LP, announced new agreements have been awarded for diagnostic imaging products and point of sale service agreements, which took effect on October 1, 2007.

The awards include the following:

Bone Densitometry - GE Healthcare of Wauwatosa, WI

Cardiovascular imaging - GE Healthcare; Philips Medical Systems of Bothell, Wash.; and Toshiba America Medical Systems of Tustin, CA.

CT - GE Healthcare, Philips Medical Systems, and Toshiba America Medical Systems.

October 10, 2007 - A new technique for capturing images of chest veins eases diagnosis of venous diseases, according to a study presented by University of Cincinnati (UC) radiologists at the North American Society of Cardiovascular Imaging's 35th Annual Meeting and Scientific Sessions in Washington, D.C.
Developed by Cristopher Meyer, M.D., and Achala Vagal, M.D., the new protocol allows radiologists to compensate for the extra time it takes contrast solution to reach the veins so useful images can be produced using the CT scanner.

Carestream Health’s KODAK DIRECTVIEW CR Mammography feature adds mammography applications to its CR platforms along with a CAD solution (both works-in-progress in the U.S.). Images from the CR platform are output onto high-resolution radiographic film with a new KODAK DRYVIEW 6800 laser imager.

The company will also demonstrate the use of its workstation with integrated CONFIRMA CADSTREAM software for breast MRI exams and CEDARA B-CAD software for breast ultrasound exams to facilitate the reading and interpretation of CAD results, along with viewing of original breast exams.

October 9, 2007 - From a snippet of a patient’s skin, researchers have grown blood vessels in a laboratory and then implanted them to restore blood flow around the patient’s damaged arteries and veins.

October 9, 2007 – Medtronic Inc. today announced that it has begun enrolling in the PRECEDE-HF clinical trial that will evaluate Medtronic’s proprietary Cardiac Compass and OptiVol Fluid Status Monitoring features to determine whether cardiac trend data may help physicians prevent heart failure hospitalizations or deaths compared to standard clinical assessment alone.

October 9, 2007 - OmniSonics Medical Technologies Inc. has received clearance from the FDA to market its catheter based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature, as the company targets the deep vein thrombosis (DVT) market.

October 9, 2007 - Ascent Healthcare Solutions announced that the FDA has cleared two Ascent 510(k) submissions to reprocess specific Medtronic and Guidant cardiac stabilization and positioner devices, for use in in Off-Pump Coronary Artery Bypass (OPCAB) procedures.

The Medtronic models include the Octopus Evolution Tissue Stabilizer (as well as the other predecessor Octopus models), Starfish and Urchin Heart Positioners. Guidant models covered under this clearance include the complete line of vacuum and mechanical systems: Xpose, Ultima and Acrobat systems.

October 9, 2007 - Physio-Control Inc., a wholly owned subsidiary of Medtronic, Inc., will introduce the LUCAS Chest Compression System in the United States through an exclusive distribution partnership with JOLIFE AB, expanding the reach of its emergency medicine device portfolio.

October 9, 2007 - Medtronic Inc. will provide a synopsis of clinical data on the Endeavor Drug Eluting Coronary Stent to be presented to an FDA Advisory Panel on October 10, 2007, which will consider whether to recommend approval of the device to the FDA.

Medtronic will submit a pooled data analysis of the major trials encompassing the ENDEAVOR clinical program as well as newly released nine-month results from the ENDEAVOR IV clinical trial. The Panel's recommendation will be subject to FDA approval.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now